Felipe P G Neves1, Nayara T Cardoso2, Robert E Snyder3, Mariel A Marlow4, Claudete A A Cardoso5, Lúcia M Teixeira6, Lee W Riley7. 1. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, 530E Li Ka Shing Center, Berkeley, CA 94720, USA; Instituto Biomédico, Universidade Federal Fluminense, Rua Professor Hernani Melo, 101 São Domingos, Niterói, RJ 24210-130, Brazil. Electronic address: fpgneves@vm.uff.br. 2. Instituto Biomédico, Universidade Federal Fluminense, Rua Professor Hernani Melo, 101 São Domingos, Niterói, RJ 24210-130, Brazil. Electronic address: nay.torresbio@gmail.com. 3. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, 530E Li Ka Shing Center, Berkeley, CA 94720, USA. Electronic address: robert.snyder@berkeley.edu. 4. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, 530E Li Ka Shing Center, Berkeley, CA 94720, USA. Electronic address: klt8@cdc.gov. 5. Faculdade de Medicina, Universidade Federal Fluminense, Av. Marquês do Paraná, 303 Centro, Niterói, RJ 24033-900, Brazil. Electronic address: claudetecardoso@id.uff.br. 6. Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373 - bloco I, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ 21941-902, Brazil. Electronic address: lmt2@micro.ufrj.br. 7. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, 530E Li Ka Shing Center, Berkeley, CA 94720, USA. Electronic address: lwriley@berkeley.edu.
Abstract
BACKGROUND: In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced free of charge in Brazil as part of the public immunization program. Here we investigated the carriage prevalence, colonization risk factors, capsular types, and antimicrobial resistance among pneumococcal isolates obtained from children in Brazil four years after routine PCV10 use. METHODS: Between September and December 2014, we conducted a cross-sectional study among children<6years old who attended one public and two private clinics in Niterói, RJ, Brazil to evaluate pneumococcal nasopharyngeal carriage. Antimicrobial susceptibility and capsular types were determined for all isolates. RESULTS: Of 522 children, 118 (22.6%) were pneumococcal carriers. Being≥2years old, attending childcare center, presenting with any symptoms, having acute or chronic respiratory disease, and residing in a slum were associated with pneumococcal carriage. The most prevalent capsular types were 6C (14.5%), 15B/C (11.5%), 11A/D (9.2%), and 6A (7.6%). PCV10 serotypes represented 2.5%. All isolates were susceptible to levofloxacin, rifampicin, and vancomycin. Penicillin non-susceptible pneumococci (PNSP) comprised 39%, with penicillin and ceftriaxone MICs ranging from 0.12-8.0μg/ml and 0.012-1.0μg/ml, respectively. The 33 (28%) erythromycin-resistant isolates (MICs of 1.5 to >256μg/ml) displayed the cMLSB (72.7%) or M (27.3%) phenotypes, harboring the erm(B) and/or mef(A/E) genes. High non-susceptibility rates (>20%) to clindamycin, erythromycin, penicillin, and tetracycline were largely explained by the prevalence of multidrug resistant (MDR) serotype 6C isolates. CONCLUSIONS: Effects of universal childhood PCV10 use on carriage were evident, with the near elimination of PCV10 serotypes. The emergence of MDR serotype 6C isolates, however, is a concern. Ongoing surveillance to monitor serotype 6C increase in invasive diseases is warranted.
BACKGROUND: In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced free of charge in Brazil as part of the public immunization program. Here we investigated the carriage prevalence, colonization risk factors, capsular types, and antimicrobial resistance among pneumococcal isolates obtained from children in Brazil four years after routine PCV10 use. METHODS: Between September and December 2014, we conducted a cross-sectional study among children<6years old who attended one public and two private clinics in Niterói, RJ, Brazil to evaluate pneumococcal nasopharyngeal carriage. Antimicrobial susceptibility and capsular types were determined for all isolates. RESULTS: Of 522 children, 118 (22.6%) were pneumococcal carriers. Being≥2years old, attending childcare center, presenting with any symptoms, having acute or chronic respiratory disease, and residing in a slum were associated with pneumococcal carriage. The most prevalent capsular types were 6C (14.5%), 15B/C (11.5%), 11A/D (9.2%), and 6A (7.6%). PCV10 serotypes represented 2.5%. All isolates were susceptible to levofloxacin, rifampicin, and vancomycin. Penicillin non-susceptible pneumococci (PNSP) comprised 39%, with penicillin and ceftriaxone MICs ranging from 0.12-8.0μg/ml and 0.012-1.0μg/ml, respectively. The 33 (28%) erythromycin-resistant isolates (MICs of 1.5 to >256μg/ml) displayed the cMLSB (72.7%) or M (27.3%) phenotypes, harboring the erm(B) and/or mef(A/E) genes. High non-susceptibility rates (>20%) to clindamycin, erythromycin, penicillin, and tetracycline were largely explained by the prevalence of multidrug resistant (MDR) serotype 6C isolates. CONCLUSIONS: Effects of universal childhood PCV10 use on carriage were evident, with the near elimination of PCV10 serotypes. The emergence of MDR serotype 6C isolates, however, is a concern. Ongoing surveillance to monitor serotype 6C increase in invasive diseases is warranted.
Authors: M P Mott; J Caierão; G R Cunha; M M Del Maschi; K Pizzutti; P d'Azevedo; C A G Dias Journal: Epidemiol Infect Date: 2019-01 Impact factor: 2.451
Authors: Matthew S Kelly; Catherine Plunkett; Yahe Yu; Jhoanna N Aquino; Sweta M Patel; Jillian H Hurst; Rebecca R Young; Marek Smieja; Andrew P Steenhoff; Tonya Arscott-Mills; Kristen A Feemster; Sefelani Boiditswe; Tirayaone Leburu; Tiny Mazhani; Mohamed Z Patel; John F Rawls; Jayanth Jawahar; Samir S Shah; Christopher R Polage; Coleen K Cunningham; Patrick C Seed Journal: ISME J Date: 2021-09-11 Impact factor: 10.302
Authors: John Njuma Libwea; Mark A Fletcher; Paul Koki Ndombo; Angeline Boula; Nadesh Taku Ashukem; Madeleine Ngo Baleba; Rachel Sandrine Kingue Bebey; Eric Gaston Nkolo Mviena; Jean Tageube; Marie Kobela Mbollo; Sinata Koulla-Shiro; Shabir Madhi; Berthe-Marie Njanpop-Lafourcade; Ali Mohammad; Elizabeth Begier; Joanna Southern; Rohini Beavon; Bradford Gessner Journal: PLoS One Date: 2021-04-15 Impact factor: 3.240
Authors: Sigríður J Quirk; Gunnsteinn Haraldsson; Helga Erlendsdóttir; Martha Á Hjálmarsdóttir; Andries J van Tonder; Birgir Hrafnkelsson; Samuel Sigurdsson; Stephen D Bentley; Ásgeir Haraldsson; Angela B Brueggemann; Karl G Kristinsson Journal: J Clin Microbiol Date: 2018-11-27 Impact factor: 5.948
Authors: Eleanor F G Neal; Cattram D Nguyen; Felista T Ratu; Eileen M Dunne; Mike Kama; Belinda D Ortika; Laura K Boelsen; Joseph Kado; Lisi Tikoduadua; Rachel Devi; Evelyn Tuivaga; Rita C Reyburn; Catherine Satzke; Eric Rafai; E Kim Mulholland; Fiona M Russell Journal: PLoS One Date: 2020-04-01 Impact factor: 3.240